Dersimelagon significantly lengthened the amount of time patients with erythropoietic protoporphyria could spend outside without experiencing any symptoms, according to NEJM.

Published Date: 28 Jul 2023

At 16 weeks, according to a study titled "Dersimelagon in Erythropoietic Protoporphyrias" that was published in the New England Journal of Medicine.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Charles III, King of Kings, is Cancerous.

2.

Chemo-Free Quadruplet Shows Promise as DLBCL's First Therapy.

3.

Perioperative Anti-PD-1 in Soft-Tissue Sarcoma Boosts Disease-Free Survival

4.

Merck enhances its oncology pipeline by means of a strategic alliance with Hengrui.

5.

WHO releases new R&D landscape analyses highlighting gaps and inequities in cancer research


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot